KCT0005701Recruiting未知
A 12 week, Multi-center, Stratified Randomized, Double-blind, Placebo-Controlled Clinical Trial for the evaluation of the efficacy and safety og GCWB106 on knee osteoarthritis
GC Wellbeing0 sites76 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 76
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- 40(Year) to 80(Year) (—)
- Sex
- All
Inclusion Criteria
- •Adult male and female between 40 years and 80 years
- •Patients diagnosed more than 30mm in VAS (Visual analogue scale)
- •Patients diagnosed grade 2, 3 with kellgren & Lawrence grading scale in X-ray
- •Those who agree to the written consent of the applicant and who can cooperate with the necessary visits and related tests and surveys for the study process
Exclusion Criteria
- •(1) Subjects with clinically significant cardiovascilar, immune, infectious and neoplastic diseases
- •(2) Subjects diagnosed with arthritis by specific factors othre than degenerative arthritis
- •(3) Subjects who is on a diet Health Functional Foods and medicine to improve joint/cartilage health
- •(4) Oriental medicine treatment of acupuncture, moxibustion, cupping therapy, herbal medicine, etc. within 2 month prior to the study
- •(5) Subjects with resistant hypertension (Upper than 160/100mmHg, After 10 minutes rest)
- •(6) Subjects with resistant diabetes (Fasting glucose levels upper than 180mg/dl)
- •(7) TSH lower than 0.1µIU/ml or upper than 10 µIU/ml
- •(8) AST(GOT) and ALT(GPT) is at least 3 timesthe normal range
- •(9) Creatinine is at least twice the normal range
- •(10) Participation in anothrt clinical trial within 2 month prior to the study
- •(11) Pregnant or nursing women
- •(12) Hypersensitivity or allergy to the test materials
- •(13) Participation who are judged to be unable to comply with the requirements of the test
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentials (ERPs) in Patients with Idiopathic Parkinson’s Disease and End-of-Dose Wearing Off.Idiopathic Parkinson’s disease and end-of-dose wearing off.MedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2007-003134-42-DEovartis Pharma Services AG20
Recruiting
Not Applicable
A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD-OF-CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA-J45J45PER-005-18OVARTIS BIOSCIENSES PERU S.A.,91
Recruiting
Not Applicable
Comparison of Entelon tab. and Celebrex cap. in patients with knee osteoarthritisDiseases of the musculo-skeletal system and connective tissueKCT0000629Hanlim Pharmaceutical336
Completed
Not Applicable
A prospective study for evaluating the validity and stability of body fat reduction when eating dandelion kimchi-derived lactobacillus in overweight or obese persons.Endocrine, nutritional and metabolic diseasesKCT0007142PHARMSVILLE100
Active, not recruiting
Not Applicable
A 12 week study to compare the effect of two medicines in one inhaler compared to placebo in COPD patientsSubjects with COPDMedDRA version: 17.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-000529-19-BGGlaxoSmithKline R&D496